Search

Your search keyword '"Bernard, JL"' showing total 5 results
Start Over Author "Bernard, JL" Journal british journal of cancer
5 results on '"Bernard, JL"'

1. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

Author

Bouffet, E, primary, Doz, F, additional, Demaille, MC, additional, Tron, P, additional, Roche, H, additional, Plantaz, D, additional, Thyss, A, additional, Stephan, JL, additional, Lejars, O, additional, Sariban, E, additional, Buclon, M, additional, Zücker, JM, additional, Brunat-Mentigny, M, additional, Bernard, JL, additional, and Gentet, JC, additional

Published
1998
Full Text
View/download PDF

2. Childhood leukaemia in Europe after Chernobyl: 5 year follow-up

Author

Parkin, DM, primary, Clayton, D, additional, Black, RJ, additional, Masuyer, E, additional, Friedl, HP, additional, Ivanov, E, additional, Sinnaeve, J, additional, Tzvetansky, CG, additional, Geryk, E, additional, Storm, HH, additional, Rahu, M, additional, Pukkala, E, additional, Bernard, JL, additional, Carli, PM, additional, L'Huillier, MC, additional, Ménégoz, F, additional, Schaffer, P, additional, Schraub, S, additional, Kaatsch, P, additional, Michaelis, J, additional, Apjok, E, additional, Schuler, D, additional, Crosignani, P, additional, Magnani, C, additional, Terracini, B, additional, Stengrevics, A, additional, Kriauciunas, R, additional, Coebergh, JW, additional, Langmark, F, additional, Zatonski, W, additional, Tulbure, R, additional, Boukhny, A, additional, Merabishvili, V, additional, Plesko, I, additional, Krámarovát, E, additional, Pompe-Kirn, V, additional, Barlow, L, additional, Enderlin, F, additional, Levi, F, additional, Raymond, L, additional, Schiüler, G, additional, Torhorst, J, additional, Stiller, CA, additional, Sharp, L, additional, and Bennett, BG, additional

Published
1996
Full Text
View/download PDF

3. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study

Author

Philip, T, primary, Ladenstein, R, additional, Zucker, JM, additional, Pinkerton, R, additional, Bouffet, E, additional, Louis, D, additional, Siegert, W, additional, Bernard, JL, additional, Frappaz, D, additional, Coze, C, additional, Wyss, M, additional, Beck, D, additional, Soulliet, G, additional, Michon, J, additional, Philip, I, additional, Chauvin, F, additional, Favrot, M, additional, and Biron, P, additional

Published
1993
Full Text
View/download PDF

5. The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.

Author

Frappaz D, Perol D, Michon J, Berger C, Coze C, Bernard JL, Zucker JM, and Philip T

Subjects
Adolescent, Carboplatin administration & dosage, Child, Child, Preschool, Cisplatin administration & dosage, Cohort Studies, Cyclophosphamide administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Humans, Infant, Male, Melphalan administration & dosage, Neuroblastoma pathology, Peripheral Blood Stem Cell Transplantation, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neuroblastoma drug therapy
Abstract

The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study was to increase progression free survival rate as compared to LMCE 1 and 3. Based on improvements reported with post induction chemotherapy, the LMCE 5 used post induction for all children, but omitted total body irradiation and immunomagnetic purging in megatherapy regimen for all children. Twenty-five sequentially diagnosed children received an induction regimen which compared with previous induction included an increased dose of etoposide and cyclophosphamide, delivered similar dose of cisplatinum, and deleted doxorubicin and vincristin. After surgery treatment was stratified based on response and eligible children received etoposide carboplatin (LMCE 5A : n=10)+/-doxorubicin (LMCE 5B-C n=13) followed by megatherapy (melphalan without total body irradiation and unpurged peripheral blood stem cell rescue). The increase in drug doses during induction did not improve remission rate. The progression free survival at 6 years is 8%. It is significantly worse than LMCE 3, and equivalent to LMCE 1 study though toxic death rate has decreased with increasing experience. Failure to improve the response rate during induction and reducing the megatherapy regimen may be the main factors in this disappointing result. Modified strategies for induction, non toxic alternative to total body irradiation, and post megatherapy regimen should be developed.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results